Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

Journal of Neurology

Volumn 250, Issue 2, 2003, Pages 171-178

  Parry, A ^a   Corkill, R ^b   Blamire, A M ^b   Palace, J ^c   Narayanan, S ^d   Arnold, D ^d   Styles, P ^b   Matthews, P M ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b MRC Biochemical and Clinical   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Axons; Beta interferon; Magnetic resonance spectroscopy; Multiple sclerosis; N acetylaspartate

Indexed keywords

BETA INTERFERON; CREATINE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; AXONAL INJURY; BRAIN LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RELAPSE;

ADULT; ASPARTIC ACID; AXONS; BODY WATER; BRAIN CHEMISTRY; COHORT STUDIES; CREATINE; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 0037320285     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0965-8     Document Type: Article

References (50)

1. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 36:76-82
2. Barnes D, McDonald WI, Johnson G, Tofts PS, Landon DN (1987) Quantitative nuclear magnetic resonance imaging: characterisation of experimental cerebral oedema. J Neurol Neurosurg Psychiatry 50:125-133
3. Barnes D, McDonald WI, Landon DN, Johnson G (1988) The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging. Brain 111 (Pt 1):83-94
4. Bhakoo KK, Pearce D (2000) In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 74:254-262
5. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 48:893-901
6. Bland JM, Altman DG (6-29-1996) Measurement error. BMJ 312:1654
7. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508:333-348
8. Dautry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, Bloch G, Hantraye P (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20:789-799
9. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB (1995) High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 64:742-748
10. De Stefano N, Matthews PM, Arnold DL (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 34:721-727
11. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121 (Pt 8):1469-1477
12. Ebers GC (2001) Natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 71 (Suppl 2):II16-II19
13. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47:391-395
14. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM (2000) Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 123 (Pt 9):1845-1849
15. Evangelou N, Trautwein A, Esiri MM (2001) Myelin loss is mainly responsible for spinal cord atrophy in MS. Multiple Sclerosis Clinical and Laboratory Research 7 (Suppl 1):S9-S9
16. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120 (Pt 3):393-399
17. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121 (Pt 1):103-113
18. Ganter P, Prince C, Esiri MM (1999) Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 25:459-467
19. Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW (1994) Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 36:157-165
20. Karlik S, Kirk S, Nicolle E, Kremenchutzky M, Rice G (2001) Evidence for very long term efficacy of interferon beta 1b in relapsing remitting MS patients. Multiple Sclerosis Clinical and Laboratory Research 7 (Supp. 1):S52-S52
21. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
22. Leary SM, Davie CA, Parker GJ, Stevenson VL, Wang L, Barker GJ, Miller DH, Thompson AJ (1999) 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 246:1023-1026
23. Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 46:197-206
24. Liu C, Edwards S, Gong Q, Roberts N, Blumhardt LD (1999) Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 66:323-330
25. Losseff NA, Miller DH (1998) Measures of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 64 (Suppl 1):S102-S105
26. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S (2000) Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123 (Pt 2):308-317
27. Matthaei D, Frahm J, Haase A, Schuster R, Bomsdorf H (2-16-1985) Chemical-shift-selective magnetic-resonance imaging of avascular necrosis of the femoral head. Lancet 1:370-371
28. Moffett JR, Namboodiri MA, Cangro CB, Neale JH (1991) Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2:131-134
29. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248:979-986
30. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, Compston DA, Miller DH (9-11-1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53:751-757
31. Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the 1FNB Multiple Sclerosis Study Group. Neurology 43:662-667
32. Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389-400
33. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
34. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (11-7-1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
35. Rooney WD, Goodkin DE, Schuff N, Meyerhoff DJ, Norman D, Weiner MW (1997) 1H MRSI of normal appearing white matter in multiple sclerosis. Mult Scler 3:231-237
36. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L (11-10-1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53:1698-1704
37. Sarchielli P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, Chiarini P, Alberti A, Vicinanza F, Gallai V (1999) Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122 (Pt 3):513-521
38. Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccloli GP, Orlacchio A, Gallai V (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64:204-212
39. Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J (1998) Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 121 (Pt 12):2221-2228
40. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study group (6-12-2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56:1496-1504
41. Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45:37-45
42. Simon JH (7-1-1999) From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunol 98:7-15
43. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH (1998) Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 43:79-87
44. Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, Waubant E, Andersson PB, Weiner MW (2000) 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 6:148-155
45. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
46. The Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
47. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1-29-1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
48. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Ader HJ, Barkhof F (1996) Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476
49. Urenjak J, Williams SR, Gadian DG, Noble M (1992) Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 59:55-61
50. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112 (Pt 1):133-146